Syndax Pharmaceuticals (NASDAQ:SNDX) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.
SNDX has been the subject of a number of other research reports. Zacks Investment Research cut shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, September 13th. HC Wainwright cut their target price on shares of Syndax Pharmaceuticals to $23.00 and set a “buy” rating for the company in a research note on Friday, October 26th. Citigroup cut their target price on shares of Syndax Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, October 11th. Finally, Morgan Stanley cut shares of Syndax Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $6.00 target price for the company. in a research note on Monday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Syndax Pharmaceuticals presently has an average rating of “Buy” and an average price target of $18.20.
Shares of NASDAQ:SNDX traded up $0.18 during trading on Thursday, reaching $4.99. The stock had a trading volume of 273,959 shares, compared to its average volume of 360,258. Syndax Pharmaceuticals has a 52 week low of $4.36 and a 52 week high of $15.20. The stock has a market capitalization of $111.29 million, a P/E ratio of -1.72 and a beta of 1.28.
Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, August 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.13. Syndax Pharmaceuticals had a negative net margin of 3,190.51% and a negative return on equity of 80.35%. The company had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.38 million. On average, analysts anticipate that Syndax Pharmaceuticals will post -3.12 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of SNDX. BlackRock Inc. raised its stake in shares of Syndax Pharmaceuticals by 11.0% in the first quarter. BlackRock Inc. now owns 1,276,671 shares of the company’s stock valued at $18,168,000 after acquiring an additional 126,941 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Syndax Pharmaceuticals by 77.7% in the first quarter. Dimensional Fund Advisors LP now owns 397,579 shares of the company’s stock valued at $5,658,000 after purchasing an additional 173,821 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Syndax Pharmaceuticals by 266.9% in the first quarter. The Manufacturers Life Insurance Company now owns 10,566 shares of the company’s stock valued at $151,000 after purchasing an additional 7,686 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its holdings in shares of Syndax Pharmaceuticals by 433.3% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 70,140 shares of the company’s stock valued at $492,000 after purchasing an additional 56,988 shares in the last quarter. Finally, Aviva PLC acquired a new stake in shares of Syndax Pharmaceuticals in the second quarter valued at approximately $423,000. Institutional investors own 64.29% of the company’s stock.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.
Featured Story: What is a bull market?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.